What is not working for the company?
What is working for the company?
|Name||Dec 22||Sep 22|
|Mutual Funds (Change:0.55)||8.18%||7.63%|
|Insurance Companies (Change:0.11)||6.18%||6.07%|
|Other DIIs (Change:-0.03)||0.58%||0.61%|
|Non Institution (Change:-0.70)||24.53%||25.23%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in NATCO PHARMA LTD
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of NATCO PHARMA LTD. (NATCOPHARM)?
Can I buy NATCO PHARMA LTD. (NATCOPHARM) shares?
How do I buy NATCO PHARMA LTD. (NATCOPHARM) from Angel One?
- Direct investment: You can buy NATCO PHARMA LTD. (NATCOPHARM) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to NATCO PHARMA LTD. (NATCOPHARM) shares.
In which sector do NATCO PHARMA LTD. (NATCOPHARM) belong?
Today's live share price for NATCO PHARMA LTD is NSE: ₹ 526.80, BSE: ₹ 528.15 with a current market capitalization of .
Incorporated in Sep.'81 as Natco Fine Pharmaceutical Ltd, it became a deemed public company with effect from Jul.'92 and in Feb.'93, it changed its name to Natco Pharma (NPL). NPL began to manufacture conventional and time-release dosage forms of life-saving drugs. NPL is a contract manufacturer for reputed companies like Ranbaxy and Parke Davis. It has also obtained the coveted ISO 9002 certification, which will boost exports. It has initiated registration proceedings (for its formulations) in over 20 countries. To channelise its operations in the US, NPL has formed a new subsidiary, Natco Pharma, US. It has entered into research collaborations with Regional Research Laboratories, Jammu, for keto-L-gluconic acid (a penultimate for iso-ascorbic acid), with the Centre for Cellular & Molecular Biology for synthetic peptides and with the Central Leather Research Institute for oral vaccines. The company has introduced drugs like diltiazem, mononitrate, etc, in time-release form. Natco Laboratories, Natco Parenterals and Karanth Pharmaceuticals have merged with the flagship company, NPL to capitalise on the opportunities in the post-GATT era, to provide a large asset base and to increase high-technology capability. During 1995-96, NPL has implemented the project for formulations in the US. As a part of its diversification plans, the company is participating in the development of Krishnapatnam Industrial Port City Project, Nellore District, in collaboration with ITOCHU, Japan; Flour Daniels, USA; and HAM, Netherlands to create infrastructure. During 1996-97, the company entered into a agreement whereby Ranbaxy Laboratories (RLL) acquires rights in marketing certain NPL's products in Russia, Ukraine and other countries of CIS. Krishnapatnam Port Project has succeeded in signinig up with the UK based Indo British Port Development Consortium to develop the project. Natco is a minority participant in this project. The Andhra Pradesh government has extended the time allowed for time closure of Krishnapatnam Port project by another 2 years. The project is now proposed to be developed in 2 phases. In the first phase,it proposed to contrct 2 berths-one for loading and another for unloading. This facility is expected to be operational by August/September,2002 and thereafter,lighterage operations could commence.Read more